$MMATQ
META MATERIALS INC. Stock $mmatq

$mmatq Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024038010 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$3.272M	$2.323M	$7.966M
YoY Change	131.7%	60.66%	-21.91%
Cost Of Revenue	$733.5K	$966.6K	$3.274M
YoY Change	-1.01%	41.57%	7.84%
Gross Profit	$2.539M	$1.356M	$4.691M
YoY Change	278.19%	77.75%	-34.51%
Gross Profit Margin	77.58%	58.38%	58.9%
Selling, General & Admin	$4.260M	$7.382M	$29.20M
YoY Change	-66.49%	-60.85%	-56.93%
% of Gross Profit	167.78%	544.33%	622.39%
Research & Development	$2.661M	$3.997M	$19.21M
YoY Change	-59.18%	-32.78%	-15.17%
% of Gross Profit	104.82%	294.76%	409.39%
Depreciation & Amortization	$995.3K	$3.453M	$13.52M
YoY Change	-33.65%	-11.34%	275.63%
% of Gross Profit	39.2%	254.61%	288.25%
Operating Expenses	$8.489M	$14.83M	$61.89M
YoY Change	-55.86%	-40.21%	-31.56%
Operating Profit	-$5.950M	-$13.47M	-$57.20M
YoY Change	-67.94%	-43.96%	-31.31%
Interest Expense	$108.8K	$1.489M	$1.245M
YoY Change	-3.75%	18.26%	614.71%
% of Operating Profit
Other Income/Expense, Net	-$1.558M	$107.1K	$6.013M
YoY Change	283.56%	-105.08%	-459.68%
Pretax Income	-$7.508M	-$79.06M	-$401.6M
YoY Change	-60.41%	278.34%	372.8%
Income Tax	$0.00	-$1.889M	-$3.344M
% Of Pretax Income
Net Earnings	-$7.500M	-$77.17M	-$398.2M
YoY Change	-59.89%	407.39%	403.45%
Net Earnings / Revenue	-229.2%	-3322.53%	-4999.36%
Basic Earnings Per Share	-$1.21		-$69.67
Diluted Earnings Per Share	-$1.21	-$13.39	-$69.10
COMMON SHARES
Basic Shares Outstanding	6.308M	490.4M	5.763M
Diluted Shares Outstanding	6.180M		5.763M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.396M	$9.724M	$9.724M
YoY Change	6.02%	-3.64%	-3.64%
Cash & Equivalents	$6.396M	$9.724M
Short-Term Investments
Other Short-Term Assets	$257.7K	$5.680M	$5.680M
YoY Change	-24.11%	1453.59%	-36.41%
Inventory	$123.9K	$168.8K	$168.8K
Prepaid Expenses	$1.254M	$1.477M
Receivables	$2.048M	$1.824M	$1.824M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.72M	$17.40M	$17.40M
YoY Change	-34.94%	-23.04%	-23.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.85M	$19.80M	$19.80M
YoY Change	-59.13%	-53.6%	-58.96%
Goodwill
YoY Change
Intangibles	$16.94M	$18.03M
YoY Change	-69.15%	-67.98%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$35.64M	$37.83M	$37.83M
YoY Change	-90.76%	-90.21%	-90.21%
TOTAL ASSETS
Total Short-Term Assets	$10.72M	$17.40M	$17.40M
Total Long-Term Assets	$35.64M	$37.83M	$37.83M
Total Assets	$46.36M	$55.23M	$55.23M
YoY Change	-88.48%	-86.49%	-86.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.697M	$10.27M	$10.27M
YoY Change	-38.51%	-38.48%	-38.48%
Accrued Expenses	$6.147M	$9.884M	$9.884M
YoY Change	522.93%	922.02%	922.02%
Deferred Revenue	$666.0K	$1.055M
YoY Change	-8.89%	44.36%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$545.2K	$1.785M	$1.785M
YoY Change	-16.82%	269.3%	269.29%
Total Short-Term Liabilities	$18.58M	$23.58M	$23.58M
YoY Change	-1.94%	19.87%	19.87%
LONG-TERM LIABILITIES
Long-Term Debt	$2.959M	$2.923M	$2.923M
YoY Change	-5.44%	-4.81%	-10.1%
Other Long-Term Liabilities	$6.485M	$6.784M	$6.784M
YoY Change	57.84%	62.53%	62.53%
Total Long-Term Liabilities	$2.959M	$9.707M	$9.707M
YoY Change	-5.44%	216.11%	30.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.58M	$23.58M	$23.58M
Total Long-Term Liabilities	$2.959M	$9.707M	$9.707M
Total Liabilities	$28.03M	$33.29M	$33.29M
YoY Change	-4.66%	9.68%	9.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$616.5M	-$609.0M
YoY Change	172.55%	193.49%
Common Stock	$639.6M	$636.4M
YoY Change	5.89%	7.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.34M	$21.94M	$21.94M
YoY Change
Total Liabilities & Shareholders Equity	$46.36M	$55.23M	$55.23M
YoY Change	-88.48%	-86.49%	-86.49%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$7.500M	-$77.17M	-$398.2M
YoY Change	-59.89%	407.39%	403.45%
Depreciation, Depletion And Amortization	$995.3K	$3.453M	$13.52M
YoY Change	-33.65%	-11.34%	275.63%
Cash From Operating Activities	-$5.900M	-$5.129M	-$42.22M
YoY Change	-61.98%	-62.64%	-32.17%
INVESTING ACTIVITIES
Capital Expenditures	$116.0K	$411.1K	$8.371M
YoY Change	-93.15%	-94.6%	-57.26%
Acquisitions
YoY Change
Other Investing Activities	$148.1K	-$430.00	$7.340M
YoY Change	-88.21%	-100.02%	6267.84%
Cash From Investing Activities	$32.10K	-$411.5K	-$1.032M
YoY Change	-107.34%	-92.74%	-94.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$42.12M
YoY Change
Debt Paid & Issued, Net	$362.8K		$522.5K
YoY Change	324.49%		-5.45%
Cash From Financing Activities	2.653M	5.565M	41.60M
YoY Change	-75.12%	68777.6%	-10.29%
NET CHANGE
Cash From Operating Activities	-5.900M	-5.129M	-42.22M
Cash From Investing Activities	32.10K	-411.5K	-1.032M
Cash From Financing Activities	2.653M	5.565M	41.60M
Net Change In Cash	-3.215M	24.88K	-1.655M
YoY Change	-39.26%	-100.13%	-95.32%
FREE CASH FLOW
Cash From Operating Activities	-$5.900M	-$5.129M	-$42.22M
Capital Expenditures	$116.0K	$411.1K	$8.371M
Free Cash Flow	-$6.016M	-$5.540M	-$50.59M
YoY Change	-65.05%	-74.04%	-38.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001431959
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Other Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4	us-gaap	Other Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration OtherReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#ImpairmentOfLongLivedAssetsHeldForUse
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2022Q2	mmat	Warrant Expiration Term WarrantExpirationTerm	P5Y6M
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36247
CY2023	dei	Entity Registrant Name EntityRegistrantName	Meta Materials Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	74-3237581
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	60 Highfield Park Drive
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Dartmouth
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NS
CY2023	dei	Entity Address Country EntityAddressCountry	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	B3A 4R9
CY2023	dei	City Area Code CityAreaCode	902
CY2023	dei	Local Phone Number LocalPhoneNumber	482-5729
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	MMAT
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	103814030
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6307684
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	Vaughan, ON, Canada
CY2023	dei	Auditor Firm AuditorFirmId	85
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9723690
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10090858
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	578406
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1720613
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	942793
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	902718
CY2023Q4	mmat	Subscription Receivables Current SubscriptionReceivablesCurrent	881100
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	2211900
CY2023Q4	us-gaap	Inventory Net InventoryNet	168747
CY2022Q4	us-gaap	Inventory Net InventoryNet	468027
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5071363
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7202099
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	29906
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	8461
CY2023Q4	us-gaap	Assets Current AssetsCurrent	17396005
CY2022Q4	us-gaap	Assets Current AssetsCurrent	22604676
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18030301
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	56313317
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18601614
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42674699
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1200417
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5576824
CY2022Q4	us-gaap	Goodwill Goodwill	281748466
CY2023Q4	us-gaap	Assets Assets	55228337
CY2022Q4	us-gaap	Assets Assets	408917982
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10270386
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6941498
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	7249291
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	9752713
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1182112
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	801628
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	483226
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1054557
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	730501
CY2023Q4	mmat	Deferred Government Assistance Current DeferredGovernmentAssistanceCurrent	590954
CY2022Q4	mmat	Deferred Government Assistance Current DeferredGovernmentAssistanceCurrent	799490
CY2023Q4	mmat	Funding Obligation Current FundingObligationCurrent	982912
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1452863
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	967126
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23584703
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19674554
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	419035
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	479808
CY2023Q4	mmat	Deferred Government Assistance Amount Noncurrent DeferredGovernmentAssistanceAmountNoncurrent	391148
CY2022Q4	mmat	Deferred Government Assistance Amount Noncurrent DeferredGovernmentAssistanceAmountNoncurrent	319017
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3253985
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5973657
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3375031
CY2022Q4	mmat	Contractual Obligation Non Current ContractualObligationNonCurrent	180705
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2922989
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3070729
CY2023Q4	us-gaap	Liabilities Liabilities	33291532
CY2022Q4	us-gaap	Liabilities Liabilities	30353829
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5659438
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5659438
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3622479
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3622479
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	543046
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	340425
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	635860437
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	590962866
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5455145
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5242810
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-609011533
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-207496328
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	21936805
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	378564153
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55228337
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	408917982
CY2023	us-gaap	Revenues Revenues	7965646
CY2022	us-gaap	Revenues Revenues	10200167
CY2023	mmat	Cost Of Goods And Service Excluding Depreciation And Amortization And Stock Based Compensation CostOfGoodsAndServiceExcludingDepreciationAndAmortizationAndStockBasedCompensation	2900290
CY2022	mmat	Cost Of Goods And Service Excluding Depreciation And Amortization And Stock Based Compensation CostOfGoodsAndServiceExcludingDepreciationAndAmortizationAndStockBasedCompensation	2426488
CY2023	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	39329
CY2022	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	65234
CY2023	mmat	Stock Based Compensation Expense Included In Cost Of Sales StockBasedCompensationExpenseIncludedInCostOfSales	334645
CY2022	mmat	Stock Based Compensation Expense Included In Cost Of Sales StockBasedCompensationExpenseIncludedInCostOfSales	544468
CY2023	us-gaap	Gross Profit GrossProfit	4691382
CY2022	us-gaap	Gross Profit GrossProfit	7163977
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4346226
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5679113
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25151098
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45413948
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19206128
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16508417
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13483380
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9207453
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-298528
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13619729
CY2023	us-gaap	Restructuring Charges RestructuringCharges	3883706
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	65580140
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	282173053
CY2023	us-gaap	Operating Expenses OperatingExpenses	413525203
CY2022	us-gaap	Operating Expenses OperatingExpenses	90428660
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-408833821
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-83264683
CY2023	us-gaap	Interest Expense InterestExpense	378657
CY2022	us-gaap	Interest Expense InterestExpense	174234
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-368522
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	35791
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1992445
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-2090238
CY2022	mmat	Gain Loss On Deconsolidation Of Wholly Owned Subsidiary GainLossOnDeconsolidationOfWhollyOwnedSubsidiary	3990737
CY2023	us-gaap	Gain Loss On Sale Of Notes Receivable GainLossOnSaleOfNotesReceivable	6750195
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-737391
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3433757
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7258070
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1671701
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-401575751
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-84936384
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3344213
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5834160
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-398231538
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-79102224
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-212335
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4945874
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-212335
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4945874
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-398443873
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-84048098
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-69.67
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-69.67
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-24.09
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-24.09
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5763446
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5763446
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3283505
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3283505
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	334708115
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-79102224
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4945874
CY2022	mmat	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	50000000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3680666
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	448711
CY2022	mmat	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	169574
CY2022	mmat	Stock Issued During Period Value Settlement Of Restricted Stock Units StockIssuedDuringPeriodValueSettlementOfRestrictedStockUnits	18027
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	67122513
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	13862031
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	378564153
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-398231538
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-212335
CY2023	mmat	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	45655464
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	5923425
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	711495
CY2023	mmat	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	91596
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	375662
CY2023	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	905733
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	21936805
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-398231538
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-79102224
CY2023	mmat	Noncash Finance Income Expense NoncashFinanceIncomeExpense	-822159
CY2022	mmat	Noncash Finance Income Expense NoncashFinanceIncomeExpense	135524
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	385170
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	403317
CY2023	mmat	Non Cash Interest Income NonCashInterestIncome	1001662
CY2023	mmat	Non Cash Lease Expense NonCashLeaseExpense	2032867
CY2022	mmat	Non Cash Lease Expense NonCashLeaseExpense	1608992
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	282173053
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3344213
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5834160
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13522756
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9272074
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	698223
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	108004
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1799977
CY2023	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-65580140
CY2023	mmat	Unrealized Loss Gain Net Excluding Foreign Currency Exchange UnrealizedLossGainNetExcludingForeignCurrencyExchange	1733024
CY2022	mmat	Unrealized Loss Gain Net Excluding Foreign Currency Exchange UnrealizedLossGainNetExcludingForeignCurrencyExchange	-2050029
CY2022	mmat	Gain Loss On Deconsolidation Of Wholly Owned Subsidiary GainLossOnDeconsolidationOfWhollyOwnedSubsidiary	3990737
CY2023	mmat	Adjustments In Contract With Customer Liability AdjustmentsInContractWithCustomerLiability	239749
CY2022	mmat	Adjustments In Contract With Customer Liability AdjustmentsInContractWithCustomerLiability	-129679
CY2023	mmat	Government Assistance GovernmentAssistance	233467
CY2022	mmat	Government Assistance GovernmentAssistance	3047
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	783
CY2023	us-gaap	Gain Loss On Sale Of Notes Receivable GainLossOnSaleOfNotesReceivable	6750195
CY2023	mmat	Stock Based Compensation And Other Non Cash Personnel Expense Recovery StockBasedCompensationAndOtherNonCashPersonnelExpenseRecovery	186401
CY2022	mmat	Stock Based Compensation And Other Non Cash Personnel Expense Recovery StockBasedCompensationAndOtherNonCashPersonnelExpenseRecovery	-13184396
CY2023	mmat	Non Cash Consulting Expense NonCashConsultingExpense	222516
CY2022	mmat	Non Cash Consulting Expense NonCashConsultingExpense	677638
CY2023	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-1784980
CY2022	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	353090
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42218910
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-62244794
CY2023	mmat	Payments For Proceeds From Property And Equipment PaymentsForProceedsFromPropertyAndEquipment	8371090
CY2022	mmat	Payments For Proceeds From Property And Equipment PaymentsForProceedsFromPropertyAndEquipment	19587511
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	39140
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	2811152
CY2023	mmat	Proceeds From Below Market Capital Government Loan ProceedsFromBelowMarketCapitalGovernmentLoan	256240
CY2022	mmat	Proceeds From Below Market Capital Government Loan ProceedsFromBelowMarketCapitalGovernmentLoan	1071862
CY2023	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	1000000
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	3486906
CY2023	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable	6083333
CY2022	mmat	Loan Advance Pursuant To Deconsolidation LoanAdvancePursuantToDeconsolidation	319987
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1031517
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19472250
CY2023	mmat	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	45655464
CY2022	mmat	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	50000000
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4340783
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3680666
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	522467
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	552579
CY2023	mmat	Proceeds From Stock Option And Warrants Exercises ProceedsFromStockOptionAndWarrantsExercises	803091
CY2022	mmat	Proceeds From Stock Option And Warrants Exercises ProceedsFromStockOptionAndWarrantsExercises	618285
CY2022	mmat	Repurchases Of Common Stock For Income Tax Withheld Upon Settlement Of Restricted Stock Units RepurchasesOfCommonStockForIncomeTaxWithheldUponSettlementOfRestrictedStockUnits	18027
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41595305
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46367013
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1655122
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-35350031
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11811471
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47434472
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	145747
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-272970
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10302096
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11811471
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	959093
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2270887
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1434186
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	288499
CY2023	mmat	Common Stock Issuance Costs In Accrued Liabilities Or Accounts Payable CommonStockIssuanceCostsInAccruedLiabilitiesOrAccountsPayable	676909
CY2023	mmat	Deemed Dividend On Warrants Upon Trigger Of Downround Feature DeemedDividendOnWarrantsUponTriggerOfDownroundFeature	3283667
CY2023	mmat	Non Cash Issuance Costs As A Result Of Amendment Warrants NonCashIssuanceCostsAsAResultOfAmendmentWarrants	905733
CY2023	mmat	Number Of Active Patent Documents NumberOfActivePatentDocuments	462
CY2023	mmat	Number Of Patents Have Issued NumberOfPatentsHaveIssued	346
CY2023	us-gaap	Substantial Doubt About Going Concern Managements Evaluation SubstantialDoubtAboutGoingConcernManagementsEvaluation	Our evaluation entails analyzing prospective operating budgets and forecasts for expectations of our cash needs and comparing those needs to the current cash and cash equivalent balances.
CY2023	us-gaap	Substantial Doubt About Going Concern Within One Year SubstantialDoubtAboutGoingConcernWithinOneYear	true
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-398200000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-79100000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-609000000
CY2023Q4	mmat	Working Capital Earnings Deficit WorkingCapitalEarningsDeficit	-6200000
CY2022Q4	mmat	Working Capital Earnings Deficit WorkingCapitalEarningsDeficit	2900000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42200000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-62200000
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reclassification </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">– Certain prior year amounts have been reclassified in the accompanying Consolidated Financial Statements to conform to the current period presentation:</span></p><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Licensing revenue is reported in a separate line under Revenue in the accompanying Consolidated Statements of Operations and Comprehensive Loss. Previously, Licensing revenue was reported as part of Development revenue. Amounts related to Licensing revenue for the year ended December 31, 2022 have been separately presented throughout this Annual Report to reflect this reclassification of Licensing revenue to conform to the current period presentation. There are no changes in total Revenue and Gross profit. </span></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and amortization expenses and stock-based compensation expense are reported in a separate line under Cost of sales and operating expenses in the accompanying Consolidated Statements of Operations and Comprehensive Loss. Previously, those expenses were reported as a same line item under Cost of sales, Sales & marketing, General & administrative and Research & development. Amounts related to depreciation and amortization expenses and stock-based compensation expense for the year ended December 31, 2022 have been separately presented throughout this Annual Report to reflect this reclassification of depreciation and amortization expenses and stock-based compensation expense to conform to the current period presentation. There are no changes in total Cost of sales, Gross profit and Operating expenses. </span></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Realized gain (loss) on foreign exchange, net and Unrealized gain (loss) on foreign exchange, net are reported in a separate line under Other income (expense), net in the accompanying Consolidated Statements of Operations and Comprehensive Loss. Previously, those expenses were reported as a single line, Gain (loss) on foreign exchange, net, under Other income (expense), net in the Consolidated Statements of Operations and Comprehensive Loss. Amounts related to depreciation and amortization expenses and stock-based compensation expense for the year ended December 31, 2022 have been separately presented throughout this Annual Report to reflect this reclassification of Realized gain (loss) on foreign exchange, net and Unrealized gain (loss) on foreign exchange to conform to the current period presentation. There are no changes in total Other income (expense), net.</span></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trade payables and Accruals and other payables are reported in a separate line in the accompanying Consolidated Balance Sheets. Previously, those items were reported as a single line, Trade and other payables, in the Consolidated Balance Sheets. Amounts related to Trade payables and Accruals and other payables as of the year ended December 31, 2022 have been separately presented to reflect this reclassification of Trade payables and Accruals and other payables to conform to the current period presentation. There are no changes in Total assets.</span></div></div>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of estimates </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">–</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of these Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and certain assumptions that affect the amounts reported in these Consolidated Financial Statements and accompanying notes. Actual results could differ from these estimates. Significant items subject to such estimates and assumptions include the valuation of goodwill, long-term assets, the valuation of net assets acquired via business combinations, and the preparation of the Consolidated Financial Statements on a going concern basis.</span></p>
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	65600000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	282200000
CY2023	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">– Consist of fees invoiced or paid by our customers for which the associated performance obligations have not been satisfied and revenue has not been recognized based on our revenue recognition criteria described above.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue is reported in a net position on an individual contract basis at the end of each reporting period and is classified as current in the consolidated balance sheet when the revenue recognition associated with the related customer payments and invoicing is expected to occur within one year of the balance sheet date and as long-term when the revenue recognition associated with the related customer payments and invoicing is expected to occur more than one year from the balance sheet date.</span></p>
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	558837
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	490077
CY2023Q4	us-gaap	Inventory Supplies Net Of Reserves InventorySuppliesNetOfReserves	10747
CY2022Q4	us-gaap	Inventory Supplies Net Of Reserves InventorySuppliesNetOfReserves	11345
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	45912
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	51589
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	43922
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	42058
CY2023Q4	mmat	Inventory Provision InventoryProvision	490671
CY2022Q4	mmat	Inventory Provision InventoryProvision	127042
CY2023Q4	us-gaap	Inventory Net InventoryNet	168747
CY2022Q4	us-gaap	Inventory Net InventoryNet	468027
CY2023	mmat	Inventory In Cost Of Goods Sold InventoryInCostOfGoodsSold	300000
CY2022	mmat	Inventory In Cost Of Goods Sold InventoryInCostOfGoodsSold	800000
CY2023	mmat	Inventory Write Down Related To Cost Of Good Sold InventoryWriteDownRelatedToCostOfGoodSold	700000
CY2022	mmat	Inventory Write Down Related To Cost Of Good Sold InventoryWriteDownRelatedToCostOfGoodSold	100000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1476981
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2835660
CY2023Q4	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	3100000
CY2022Q4	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	0
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	332794
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	365583
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	161588
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	4000856
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5071363
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7202099
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	62301597
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	52954295
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	43699983
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10279596
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18601614
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42674699
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	65600000
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	100000
CY2023	us-gaap	Depreciation Depreciation	6500000
CY2022	us-gaap	Depreciation Depreciation	3600000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	67294055
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	65811004
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	49263754
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9497687
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18030301
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	56313317
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7000000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5700000
CY2021Q4	us-gaap	Goodwill Goodwill	240376634
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	42343552
CY2022	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	1446639
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-2418359
CY2022Q4	us-gaap	Goodwill Goodwill	281748466
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-424587
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	282173053
CY2023	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	282200000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	3724617
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	3553955
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	801628
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	483226
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2922989
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3070729
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	mmat	Non Cash Issuance Cost NonCashIssuanceCost	900000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	214046
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	46
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M2D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	56924556
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	143190
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	140.74
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	16885
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	27
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4401
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	102.37
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	335950
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	80
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M21D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	17611251
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	62961
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.58
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	26351
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	27
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	183020
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	84.75
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	189540
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	62.23
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y8M4D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	121356
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	69.97
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y8M1D
CY2023Q4	mmat	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding	189540
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	121356
CY2022Q4	mmat	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOutstanding	335950
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	243276
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	81
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.87
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.81
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0416
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0256
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y25D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y2M8D
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-305558883
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-58490568
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-96016868
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-26445816
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-401575751
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-84936384
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	1737
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	1256
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1737
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1256
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-4893000
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-3345950
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-942416
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3345950
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5835416
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3344213
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5834160
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-84364447
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-17836641
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1735944
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1428381
CY2023	mmat	Effective Income Tax Rate Reconciliation Capital Loss EffectiveIncomeTaxRateReconciliationCapitalLoss	910340
CY2022	mmat	Effective Income Tax Rate Reconciliation Capital Loss EffectiveIncomeTaxRateReconciliationCapitalLoss	7192458
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	59242764
CY2023	mmat	Effective Income Tax Rate Reconciliation Other Permanent Items EffectiveIncomeTaxRateReconciliationOtherPermanentItems	1697269
CY2022	mmat	Effective Income Tax Rate Reconciliation Other Permanent Items EffectiveIncomeTaxRateReconciliationOtherPermanentItems	-3750116
CY2022	mmat	Income Tax Reconciliation Foreign Currency And Other IncomeTaxReconciliationForeignCurrencyAndOther	185860
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	508993
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	319137
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-5405405
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1484069
CY2023	mmat	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	-11394
CY2022	mmat	Effective Income Tax Rate Reconciliation Provision To Return EffectiveIncomeTaxRateReconciliationProvisionToReturn	1595074
CY2023	mmat	Effective Income Tax Rate Reconciliation Deferred True Ups EffectiveIncomeTaxRateReconciliationDeferredTrueUps	1674700
CY2022	mmat	Effective Income Tax Rate Reconciliation Deferred True Ups EffectiveIncomeTaxRateReconciliationDeferredTrueUps	1525095
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	26977577
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	22870613
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3344213
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5834160
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0083
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0687
CY2023Q4	mmat	Deferred Tax Asset Non Capital Losses DeferredTaxAssetNonCapitalLosses	39878943
CY2022Q4	mmat	Deferred Tax Asset Non Capital Losses DeferredTaxAssetNonCapitalLosses	30527370
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	7564389
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	7228389
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5346259
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5718562
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	4609247
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5031651
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2824760
CY2023Q4	mmat	Deferred Tax Assets Research And Development Expense Capitalization DeferredTaxAssetsResearchAndDevelopmentExpenseCapitalization	3888782
CY2022Q4	mmat	Deferred Tax Assets Research And Development Expense Capitalization DeferredTaxAssetsResearchAndDevelopmentExpenseCapitalization	2198314
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1955147
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1144703
CY2023Q4	mmat	Deferred Tax Assets Right Of Use Asset DeferredTaxAssetsRightOfUseAsset	1607756
CY2022Q4	mmat	Deferred Tax Assets Right Of Use Asset DeferredTaxAssetsRightOfUseAsset	808717
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	7063161
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	89934
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	72895
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	173453
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	37426
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	72599475
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	55170383
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	68666432
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41688855
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3933043
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	13481528
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	3658773
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	12355386
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2791147
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	134855
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1234015
CY2023Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	139415
CY2022Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	189260
CY2022Q4	mmat	Deferred Tax Liabilities Funding Obligation DeferredTaxLiabilitiesFundingObligation	112974
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	52731
CY2022Q4	mmat	Deferred Government Assistance Current DeferredGovernmentAssistanceCurrent	799490
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3933043
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	16735513
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3253985
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	143900000
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	111400000
CY2023Q4	mmat	Deferred Tax Assets Net Operating Loss Carryforwards And Differences From Financial Instruments DeferredTaxAssetsNetOperatingLossCarryforwardsAndDifferencesFromFinancialInstruments	72600000
CY2022Q4	mmat	Deferred Tax Assets Net Operating Loss Carryforwards And Differences From Financial Instruments DeferredTaxAssetsNetOperatingLossCarryforwardsAndDifferencesFromFinancialInstruments	55200000
CY2023	mmat	Net Operating Loss Carry Forward Expiration Year Starting NetOperatingLossCarryForwardExpirationYearStarting	2028
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	68700000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41700000
CY2023	mmat	Net Loss NetLoss	-398231538
CY2022	mmat	Net Loss NetLoss	-79102224
CY2023	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	3283667
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-401515205
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-79102224
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5763446
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3283505
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5763446
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3283505
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-69.67
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-24.09
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-69.67
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-24.09
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2304802
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	839331
CY2023	mmat	Increase Decrease In Grants Receivable IncreaseDecreaseInGrantsReceivable	3689
CY2022	mmat	Increase Decrease In Grants Receivable IncreaseDecreaseInGrantsReceivable	-172765
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	372601
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	319116
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	29357
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-287320
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2530367
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4799174
CY2023	mmat	Increase Decrease In Trade Payables And Other Accruals IncreaseDecreaseInTradePayablesAndOtherAccruals	22428
CY2022	mmat	Increase Decrease In Trade Payables And Other Accruals IncreaseDecreaseInTradePayablesAndOtherAccruals	5410515
CY2023	us-gaap	Restructuring Costs RestructuringCosts	1181781
CY2022	us-gaap	Restructuring Costs RestructuringCosts	0
CY2023	mmat	Increase Decrease In Due From To Related Parties Current IncreaseDecreaseInDueFromToRelatedPartiesCurrent	21666
CY2022	mmat	Increase Decrease In Due From To Related Parties Current IncreaseDecreaseInDueFromToRelatedPartiesCurrent	108102
CY2023	mmat	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	0
CY2022	mmat	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	231
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1522283
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-997067
CY2023	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-1784980
CY2022	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	353090
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	65600000
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7965646
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10200167
CY2021Q4	mmat	Development Contract Value DevelopmentContractValue	41500000
CY2021	mmat	Development Contract Period Maximum DevelopmentContractPeriodMaximum	P5Y
CY2023Q3	mmat	Development Contract Value DevelopmentContractValue	2100000
CY2023Q3	mmat	Development Contract Value DevelopmentContractValue	6200000
CY2023Q4	mmat	Development Contract Value DevelopmentContractValue	22700000
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	200000
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	100000
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	1200000
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	1400000
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	1473592
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	1210309
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1054557
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	730501
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	419035
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	479808
CY2023Q4	mmat	Deferred Government Assistance DeferredGovernmentAssistance	982102
CY2022Q4	mmat	Deferred Government Assistance DeferredGovernmentAssistance	1118507
CY2023Q4	mmat	Deferred Government Assistance Current DeferredGovernmentAssistanceCurrent	590954
CY2023Q4	mmat	Deferred Government Assistance Non Current DeferredGovernmentAssistanceNonCurrent	391148
CY2022Q4	mmat	Deferred Government Assistance Non Current DeferredGovernmentAssistanceNonCurrent	319017
CY2023	mmat	Government Assistance Income Recognized GovernmentAssistanceIncomeRecognized	582756
CY2022	mmat	Government Assistance Income Recognized GovernmentAssistanceIncomeRecognized	218532
CY2023	mmat	Other Income Nonoperating OtherIncomeNonoperating	335163
CY2022	mmat	Other Income Nonoperating OtherIncomeNonoperating	72038
CY2023	mmat	Fair Value Gain Loss On Long Term Debt FairValueGainLossOnLongTermDebt	-53711
CY2022	mmat	Fair Value Gain Loss On Long Term Debt FairValueGainLossOnLongTermDebt	56185
CY2023	mmat	Fair Value Gain Loss On Funding Obligation FairValueGainLossOnFundingObligation	-768449
CY2022	mmat	Fair Value Gain Loss On Funding Obligation FairValueGainLossOnFundingObligation	79339
CY2023	mmat	Scientific Research And Experimental Development Government Assistance Income Recognized ScientificResearchAndExperimentalDevelopmentGovernmentAssistanceIncomeRecognized	434517
CY2023	mmat	Deferred Government Assistance Income Recognized DeferredGovernmentAssistanceIncomeRecognized	85915
CY2023	mmat	Payroll Subsidies Income PayrollSubsidiesIncome	62324
CY2022	mmat	Payroll Subsidies Income PayrollSubsidiesIncome	77075
CY2022	mmat	Amortizations Of Deferred Government Assistance AmortizationsOfDeferredGovernmentAssistance	3047
CY2022	mmat	Research And Development Tax Credit Amount ResearchAndDevelopmentTaxCreditAmount	138410
CY2023	mmat	Government Assistance Income Recognized GovernmentAssistanceIncomeRecognized	582756
CY2022	mmat	Government Assistance Income Recognized GovernmentAssistanceIncomeRecognized	218532
CY2023	mmat	Non Cash Interest Accretion NonCashInterestAccretion	372000
CY2022	mmat	Non Cash Interest Accretion NonCashInterestAccretion	403317
CY2023	mmat	Interest Bank Charges InterestBankCharges	55756
CY2022	mmat	Interest Bank Charges InterestBankCharges	-133518
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	49099
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	95565
CY2023	us-gaap	Interest Expense InterestExpense	378657
CY2022	us-gaap	Interest Expense InterestExpense	174234
CY2023	mmat	Oil And Gas Assets Maintenance Cost OilAndGasAssetsMaintenanceCost	0
CY2022	mmat	Oil And Gas Assets Maintenance Cost OilAndGasAssetsMaintenanceCost	3859851
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1799977
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2023	mmat	Interest Income From Next Bridge InterestIncomeFromNextBridge	966827
CY2022	mmat	Interest Income From Next Bridge InterestIncomeFromNextBridge	0
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-737391
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3433757
CY2019Q2	mmat	Number Of Funding Tranches NumberOfFundingTranches	2
CY2019Q2	mmat	Number Of Milestones Achieved NumberOfMilestonesAchieved	2
CY2019Q2	mmat	Proceeds From Funding Obligation Upon Achievement Of Milestone ProceedsFromFundingObligationUponAchievementOfMilestone	1300000
CY2019Q2	mmat	Percentage Of Sales Revenue Used For Repayment Of Funds PercentageOfSalesRevenueUsedForRepaymentOfFunds	0.10
CY2023Q4	mmat	Outstanding Funding Obligation OutstandingFundingObligation	982912
CY2022Q4	mmat	Outstanding Funding Obligation OutstandingFundingObligation	959835
CY2022Q4	mmat	Fair Value Of Interest Free Component Of Funding Obligation FairValueOfInterestFreeComponentOfFundingObligation	-852573
CY2023Q4	mmat	Principal Adjusted For Interest Free Component Of Funding Obligation PrincipalAdjustedForInterestFreeComponentOfFundingObligation	982912
CY2022Q4	mmat	Principal Adjusted For Interest Free Component Of Funding Obligation PrincipalAdjustedForInterestFreeComponentOfFundingObligation	107262
CY2022Q4	mmat	Accumulated Non Cash Interest Accretion AccumulatedNonCashInterestAccretion	73443
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	982912
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	180705
CY2023Q4	mmat	Contractual Obligation Current ContractualObligationCurrent	982912
CY2022Q4	mmat	Contractual Obligation Non Current ContractualObligationNonCurrent	180705
CY2019	mmat	Funding Obligation Effective Interest Rate FundingObligationEffectiveInterestRate	0.15
CY2022	mmat	Funding Obligation Effective Interest Rate FundingObligationEffectiveInterestRate	0.1917
CY2022	mmat	Gain Loss On Funding Obligation GainLossOnFundingObligation	100000
CY2023	mmat	Non Cash Adjustment To Funding Obligation NonCashAdjustmentToFundingObligation	800000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2248287
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2057157
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	311107
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	584645
CY2023	mmat	Variable And Other Lease Expense VariableAndOtherLeaseExpense	533621
CY2022	mmat	Variable And Other Lease Expense VariableAndOtherLeaseExpense	263500
CY2023	us-gaap	Lease Cost LeaseCost	3093015
CY2022	us-gaap	Lease Cost LeaseCost	2905302
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	6900000
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1969721
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1732924
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1590697
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1172341
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1180761
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	3834677
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11481121
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4054601
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7426520
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1452863
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5973657
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1284
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1717
CY2023	us-gaap	Restructuring And Related Activities Initiation Date RestructuringAndRelatedActivitiesInitiationDate	2023-06-06
CY2023	us-gaap	Restructuring Charges RestructuringCharges	3900000
CY2023Q4	mmat	Provisions For Severance Payments ProvisionsForSeverancePayments	1200000
CY2023Q4	mmat	Contract Termination Costs ContractTerminationCosts	1200000
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	2700000
CY2023	mmat	Non Cash Impairment Loss NonCashImpairmentLoss	65600000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7965646
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10200167
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18601614
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42674699
CY2023	mmat	Payments Of Civil Money Penalty Amount PaymentsOfCivilMoneyPenaltyAmount	1000000
CY2023Q4	mmat	Number Of Installments In Civil Money Penalty Amount NumberOfInstallmentsInCivilMoneyPenaltyAmount	4
CY2023	us-gaap	Royalty Expense RoyaltyExpense	0
CY2022	us-gaap	Royalty Expense RoyaltyExpense	0
CY2024Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-one hundred

Files In Submission

Name	View Source	Status
0000950170-24-038010-index-headers.html	Edgar Link	pending
0000950170-24-038010-index.html	Edgar Link	pending
0000950170-24-038010.txt	Edgar Link	pending
0000950170-24-038010-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mmat-20231231.htm	Edgar Link	pending
mmat-20231231.xsd	Edgar Link	pending
mmat-ex21_1.htm	Edgar Link	pending
mmat-ex23_1.htm	Edgar Link	pending
mmat-ex31_1.htm	Edgar Link	pending
mmat-ex32_1.htm	Edgar Link	pending
mmat-ex4_5.htm	Edgar Link	pending
mmat-ex97.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
mmat-20231231_htm.xml	Edgar Link	completed
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MMATQ
META MATERIALS INC. Stock $mmatq

2024 Q1 Form 10-K Financial Statement

#000095017024038010 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MMATQ META MATERIALS INC. Stock $mmatq

2024 Q1 Form 10-K Financial Statement

#000095017024038010 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MMATQ
META MATERIALS INC. Stock $mmatq